Comprehensive Joint Modeling of First-Line Therapeutics in Non-Small Cell Lung Cancer
Schneider, B. K.; Benzekry, S.; Mochel, J. P.
Show abstract
First-line antiproliferatives for non-small cell lung cancer (NSCLC) have a relatively high failure rate due to high intrinsic resistance rates and acquired resistance rates to therapy. 57% patients are diagnosed in late-stage disease due to the tendency of early-stage NSCLC to be asymptomatic. For patients first diagnosed with metastatic disease the 5-year survival rate is approximately 5%. To help accelerate the development of novel therapeutics and computer-based tools for optimizing individual therapy, we have collated data from 11 different clinical trials in NSCLC and developed a semi-mechanistic, clinical model of NSCLC growth and pharmacodynamics relative to the various therapeutics represented in the study. In this study, we have produced extremely precise estimates of clinical parameters fundamental to cancer modeling such as the rate of acquired resistance to various pharmaceuticals, the relationship between drug concentration and rate of cancer cell death, as well as the fine temporal dynamics of anti-VEGF therapy. In the simulation sets documented in this study, we have used the model to make meaningful descriptions of efficacy gain in making bevacizumab-antiproliferative combination therapy sequential, over a series of days, rather than concurrent.
Matching journals
The top 8 journals account for 50% of the predicted probability mass.
Similar papers in this journal
Similar papers in this journal
- Simulating clinical trials for model-informed precision dosing: Using warfarin treatment as a use case 92%
- stormTB: A web-based simulator of a murine minimal-PBPK model for anti-tuberculosis treatments. 91%
- Informing Pharmacokinetic Models with Physiological Data: Oral Population Modeling of L-Serine in Humans 91%
Similar papers in this journal
Similar papers in this journal
- Early prediction of clinical response to checkpoint inhibitor therapy in human solid tumors through mathematical modeling 95%
- Multidisciplinary analysis of evolution based Abiraterone treatment for metastatic castrate resistant prostate cancer 92%
- Patient-specific Boolean models of signaling networks guide personalized treatments 91%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.